DelveInsight has launched a new report on Exocrine Pancreatic Insufficiency Market Insights, Epidemiology and Market Forecast-2030
DelveInsight’s “Exocrine Pancreatic Insufficiency (EPI) – Market Insights, Epidemiology, and Market Forecast-2030” report delivers an in-depth understanding of the Exocrine Pancreatic Insufficiency (EPI) , historical and forecasted epidemiology as well as the Exocrine Pancreatic Insufficiency (EPI) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
The Exocrine Pancreatic Insufficiency (EPI) market report provides current treatment practices, emerging drugs, Exocrine Pancreatic Insufficiency (EPI) market share of the individual therapies, current and forecasted Exocrine Pancreatic Insufficiency (EPI) market Size from 2017 to 2030 segmented by seven major markets. The Report also covers current Exocrine Pancreatic Insufficiency (EPI) treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assesses the underlying potential of the market.
Exocrine Pancreatic Insufficiency (EPI) is a degenerative disease caused by the insufficient production and secretion of pancreatic digestive enzymes which leads to maldigestion (an inability to breakdown nutrients) in the duodenum. It is commonly caused by a reduction in functioning pancreatic tissue or ductal disease, such as in chronic pancreatitis and pancreatic malignancy. It can also result from reduced enterohormonal stimulation of the pancreas in severe duodenal mucosal disease, and from anatomical changes following gastrointestinal surgery. The condition is associated with significant morbidity and reductions in quality of life, even in milder forms.
“As per the study conducted by M. Othman et al. (2018), the prevalence of EPI can be quite high among certain sub-groups of individuals such as those with chronic pancreatitis (CP), cystic fibrosis (CF), pancreatic cancer, and pancreas resection. EPI may be particularly common whenever diarrhea is present, whether with IBS (6%) or coeliac disease, despite adopting a gluten-free diet (30%). Further, the prevalence of EPI also appears to increase with age”
1. Solvay Pharmaceuticals 2. Janssen Pharmaceuticals3. Adare Pharma Co. 4. Repha GmbH
Name of drugs covered that are given below:-
1. Creon2. Pancreaze3. Zenpep4. Nortase
1. Key Insights
2. Executive Summary of Exocrine Pancreatic Insufficiency (EPI)
3. Competitive Intelligence Analysis for Exocrine Pancreatic Insufficiency (EPI)
4. Exocrine Pancreatic Insufficiency (EPI) : Market Overview at a Glance
4.1. Exocrine Pancreatic Insufficiency (EPI) Total Market Share (%) Distribution in 2017
4.2. Exocrine Pancreatic Insufficiency (EPI) Total Market Share (%) Distribution in 2030
5. Exocrine Pancreatic Insufficiency (EPI) : Disease Background and Overview
6. Patient Journey
7. Exocrine Pancreatic Insufficiency (EPI) Epidemiology and Patient Population
8. Treatment Algorithm, Current Treatment, and Medical Practices
8.1. Exocrine Pancreatic Insufficiency (EPI) Treatment and Management
8.2. Exocrine Pancreatic Insufficiency (EPI) Treatment Algorithm
9. Unmet Needs
10. Key Endpoints of Exocrine Pancreatic Insufficiency (EPI) Treatment
11. Marketed Products
12. Emerging Therapies
13. Exocrine Pancreatic Insufficiency (EPI) : Seven Major Market Analysis
13.1. Key Findings
13.2. Exocrine Pancreatic Insufficiency (EPI) Market Size in 7MM
13.3. Exocrine Pancreatic Insufficiency (EPI) Market Size by Therapies in the 7MM
14. Attribute analysis
15. 7MM: Market Outlook
16. Access and Reimbursement Overview of Exocrine Pancreatic Insufficiency (EPI)
17. KOL Views
18. Market Drivers
19. Market Barriers
20. Appendix
20.1. Bibliography
20.2. Report Methodology
21. DelveInsight Capabilities
22. Disclaimer
23. About DelveInsight
Why should you buy this report?
Related Reports:-
1. Exocrine Pancreatic Insufficiency (EPI) – Epidemiology Forecast to 2030
2. Exocrine Pancreatic Insufficiency- Market Insight, Epidemiology and Market Forecast -2030
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Yash BhardwajEmail: Send EmailPhone: +919650213330Address:304 S. Jones Blvd #2432 City: AlbanyState: New YorkCountry: United StatesWebsite: https://www.delveinsight.com/